- Investigator
- Francesco Franchi
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
Treats Adults
Francesco Franchi, MD
Cardiologist
- Additional languages:
- Italian
(904) 383-1011
Request appointment online
Research at a glance
Top areas of exploration
- Platelet Aggregation Inhibitors , 83 publications
- Percutaneous Coronary Intervention , 49 publications
- Purinergic P2Y Receptor Antagonists , 43 publications
- Clopidogrel , 36 publications
Research activity
Active clinical trials
- Investigator
- Francesco Franchi
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
- Investigator
- Francesco Franchi
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
My publications
Filter publications
143 publications
2022
Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation.
Clinical pharmacology and therapeutics
鈥�2022
Patterns and Outcomes of Dual聽Antiplatelet Therapy Discontinuation After Percutaneous聽Coronary Intervention.
JACC. Cardiovascular interventions
鈥�2022
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
European heart journal
鈥�2022
CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.
Journal of the American Heart Association
鈥�2022
Reply: The Effects of Cangrelor on Platelet Aggregation in STEMI Patients: Methodological or Pharmacological Issues?
JACC. Cardiovascular interventions
鈥�